BioSpace News Archive

OLEO Advances CBD Supplement Research To Be The First Athletic Drink Mix Containing CBD

Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthrough Therapy designation for low platelet counts in people exposed to radiation

Last month, the U.S. Department of Agriculture and the U.S. Food and Drug Administration held a public meeting to discuss the use of livestock and poultry cell lines to develop cell-cultured food products.

Gala Raises $500,000 Towards Providing Affordable Treatment

Johnson Fistel, LLP announced that a class action has been commenced on behalf of purchasers of Trevena, Inc. (NASDAQ:TRVN) common stock during the period between May 2, 2016 and October 9, 2018 (the “Class Period”).

A individual participant in Nordic Nanovector ASA’s previous share option program, not being a primary insider, has exercised a total number of 300,000 options through exercise of a corresponding number of free-standing warrants. 185,421 of the options are exercised at a strike price of NOK 25 per share, and 114,579 of the options are exercised at a strike price of NOK 14.24 per share.

BioPharmX Corporation announced that on November 1, 2018, NYSE Regulation accepted the Company’s plan to regain compliance with the NYSE American LLC (“NYSE American”) continued listing standards set forth in Sections 1003(a)(iii) of the NYSE American Company Guide.

Kodiak Sciences Inc.today reported business highlights and financial results for the third quarter ended September 30, 2018.

CASI Pharmaceuticals, Inc. announces that it has entered into framework agreements to build a state-of-the-art manufacturing site strategically located in the Wuxi Huishan Economic Development Zone in Jiangsu Province, China.

4D Molecular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to 4D-110 for the treatment of choroideremia.